ROS–Responsive Ferrocenyl Amphiphilic PAMAM Dendrimers for On–Demand Delivery of siRNA Therapeutics to Cancer Cells
Pharmaceutics · 13.07.2024 · 16 (7) · 936
DOI: 10.3390/pharmaceutics16070936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.07.2024. Verfasst von Peng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Advanced Pharmaceuticals and Biomaterials, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, Chin…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology innovation project from National Center of Tech-nology Innovation for Biopharma-ceuticals, the National Natural Science Foundation of China, National Key Research & Development Program of China for International S&T Cooperation Projects.
Abstract (Originalsprache)
Small interfering RNA (siRNA) therapeutics, characterized by high specificity, potency, and durability, hold great promise in the treatment of cancer and other diseases. However, the clinic implementation of siRNA therapeutics critically depends on the safe and on–demand delivery of siRNA to the target cells. Here, we reported a family of ferrocenyl amphiphilic dendrimers (Fc-AmDs) for on–demand delivery of siRNA in response to the high ROS content in cancer cells. These dendrimers bear ROS–sensitive ferrocene moieties in the hydrophobic components and positively chargeable poly(amidoamine) dendrons as the hydrophilic entities, possessing favorable safety profiles and ROS responsive properties. One of these ferrocenyl amphiphilic dendrimers, Fc-C8-AmD 8A, outperforms in siRNA delivery, benefiting from its optimal balance of hydrophobicity and hydrophilicity. Its ROS feature facilitates specific and efficient disassembly of its complex with siRNA in ROS–rich cancer cells for effective siRNA delivery and gene silencing. Moreover, Fc-C8-AmD 8A also integrates the features and beneficial properties of both lipid and dendrimer vectors. Therefore, it represents a novel on–demand delivery system for cancer cell–specific siRNA delivery. This work opens new perspectives for designing self–assembly nanosystems for on–demand drug delivery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Advanced Pharmaceuticals and Biomaterials, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China.
ORCID-Profile: Peng Chen, Dandan Zhu, Xiaoxuan Liu
Förderung
- Technology innovation project from National Center of Tech-nology Innovation for Biopharma-ceuticals
- the National Natural Science Foundation of China
- National Key Research & Development Program of China for International S&T Cooperation Projects
- National Center of Technology Innovation for Biopharmaceuticals
- National Natural Science Foundation of China
- Youth Thousand-Talents Program of China
- National Key Research & Development Program of China for International S&T Cooperation Projects
Zitieren
APA
Chen, P., Wang, Z., Wang, X., Gong, J., Sheng, J., Pan, Y., Zhu, D., & Liu, X. (2024). ROS–Responsive Ferrocenyl Amphiphilic PAMAM Dendrimers for On–Demand Delivery of siRNA Therapeutics to Cancer Cells. Pharmaceutics, 16(7), 936. https://doi.org/10.3390/pharmaceutics16070936
Vancouver
Chen P, Wang Z, Wang X, Gong J, Sheng J, Pan Y, et al. ROS–Responsive Ferrocenyl Amphiphilic PAMAM Dendrimers for On–Demand Delivery of siRNA Therapeutics to Cancer Cells. Pharmaceutics. 2024;16(7):936. doi:10.3390/pharmaceutics16070936
BibTeX
@article{Chen2024,
author = {Chen, Peng and Wang, Zhihui and Wang, Xinmo and Gong, Junni and Sheng, Ju and Pan, Yufei and Zhu, Dandan and Liu, Xiaoxuan},
title = {ROS–Responsive Ferrocenyl Amphiphilic PAMAM Dendrimers for On–Demand Delivery of siRNA Therapeutics to Cancer Cells},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {7},
pages = {936},
doi = {10.3390/pharmaceutics16070936}
}
EUVIMED